

## This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Cancer</b>				
Melanoma	Melanoma-overexpressed antigen-1 (MELOE-1)	<p>A study in melanoma patients suggests that MELOE-1 could potentially be used for melanoma immunotherapy. Transcription analysis showed that MELOE-1 is highly expressed in major histocompatibility complex class I A2 (HLA-A2) melanomas compared with that seen in both other HLA-A2-expressing cancers and in normal melanocytes. Also, five of nine nonrelapse patients had MELOE-1-specific T cells, whereas equivalent immune cells were not detected in 21 relapsed patients. Further studies are necessary to determine a method for transferring MELOE-1-specific T cells to melanoma patients.</p> <p>At least 16 companies have melanoma immunotherapies in development stages ranging from clinical to marketed.</p> <p><b>SciBX 1(40); doi:10.1038/scibx.2008.968</b>  <b>Published online Nov. 6, 2008</b></p>	Findings patented; 15 applications covered by the patent, including specific lymphocytes for adoptive therapy and detection methods for diagnosis, are available for licensing	<p>Godet, Y. <i>et al. J. Exp. Med.</i>; published online Oct. 20, 2008;            doi:10.1084/jem.20081356  <b>Contact:</b> Nathalie Labarriere, Institut National de la Santé et de la Recherche Médicale (INSERM), Nantes, France            e-mail:  <a href="mailto:nlabar@nantes.inserm.fr">nlabar@nantes.inserm.fr</a></p>